List of Excipients in Branded Drug VALTOCO

VALTOCO Excipient Strategy and Commercial Opportunities in Diazepam Nasal Rescue

Last updated: August 25, 2026

VALTOCO is a prescription diazepam nasal spray developed by Neurelis, Inc. for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity in patients with epilepsy who are maintained on stable regimens of antiepileptic drugs. Its commercial differentiation is based on intranasal delivery, single-use administration, four weight- and age-based strengths, and a formulation designed for rapid systemic absorption without refrigeration or patient assembly.[1]

The excipient strategy supports three commercial objectives: maintain diazepam in a stable nasal solution, promote absorption across the nasal mucosa, and simplify administration for caregivers. The main opportunity for competitors is not a conventional tablet-to-tablet generic substitution. It is a formulation and device challenge involving nasal tolerability, dose delivery, stability, human-factors performance, and FDA approval under an abbreviated or hybrid regulatory pathway.

What is VALTOCO and how does its formulation create commercial value?

VALTOCO contains diazepam in a ready-to-use nasal spray. It is supplied in 5 mg, 10 mg, 15 mg, and 20 mg doses. The 5 mg and 10 mg products are administered as one spray into one nostril. The 15 mg and 20 mg doses require two devices, with one spray administered into each nostril.[1]

Attribute	VALTOCO commercial design
Active ingredient	Diazepam
Dosage form	Single-dose nasal spray
Approved strengths	5 mg, 10 mg, 15 mg, 20 mg
Administration	One or two single-use devices, depending on dose
Target use	Acute rescue treatment for seizure clusters
Approval pathway	FDA 505(b)(2) NDA
Applicant	Neurelis, Inc.
FDA approval	January 2020
Storage	Room-temperature storage under labeled conditions
Primary user	Caregiver or trained patient
Key differentiation	Needle-free, nonoral rescue delivery

The product’s commercial value comes from reducing dependence on rectal administration, which can create privacy, positioning, and caregiver-acceptance barriers. It also avoids the need for the patient to swallow during an acute seizure event.

What excipients are used in VALTOCO?

The VALTOCO label identifies diazepam, vitamin E, and dehydrated alcohol among the formulation components.[1] The formulation is a clear solution rather than a suspension or powder. That choice reduces the need for shaking and supports dose uniformity through a metered nasal device.

Excipient or formulation component	Likely technical function	Commercial relevance
Vitamin E, or alpha-tocopherol	Solubilization and formulation stabilization	Helps maintain diazepam in a concentrated nasal solution
Dehydrated alcohol	Cosolvent	Supports diazepam solubility and low-volume delivery
Diazepam	Active pharmaceutical ingredient	Benzodiazepine rescue therapy

The formulation uses a relatively small administration volume. That matters because excessive nasal volume can cause runoff into the throat, swallowing, leakage, and inconsistent deposition. A low-volume solution also supports use of a compact single-dose actuator.

Why is vitamin E commercially important?

Vitamin E is a key differentiator in the formulation strategy. Diazepam has limited water solubility, so a nasal product requires a solvent system that can dissolve the active ingredient while remaining acceptable for nasal administration.

Vitamin E can function as a lipophilic solubilizing and stabilizing component. Its use may help avoid more aggressive surfactant systems or highly acidic and alkaline pH conditions. That creates a formulation profile aimed at balancing:

• Diazepam solubility.
• Nasal-tissue tolerability.
• Chemical stability.
• Spray performance.
• Container compatibility.
• Low administration volume.

A competitor seeking to design around VALTOCO may replace vitamin E with another solubilizer, cosolvent, complexing agent, or self-emulsifying system. The substitute would need to match VALTOCO on delivered dose, absorption rate, nasal tolerability, stability, and device compatibility. A nominally different excipient does not eliminate risk if patent claims cover the overall formulation, concentration ranges, delivery volume, or functional properties.

What role does dehydrated alcohol play?

Dehydrated alcohol acts primarily as a cosolvent for diazepam. It permits a concentrated solution in a small nasal spray volume. Its use also imposes development constraints.

A competing product must evaluate:

• Nasal irritation and burning.
• Volatility during filling and storage.
• Extractables and leachables from the container closure system.
• Flammability controls during manufacturing.
• Changes in concentration caused by evaporation.
• Compatibility with the pump, actuator, and dose chamber.

The presence of alcohol does not automatically make a product noncompetitive. Its commercial impact depends on concentration, residual exposure, device sealing, and clinical tolerability.

What formulation patents protect VALTOCO?

VALTOCO protection is expected to involve multiple layers rather than a single composition claim. The relevant intellectual-property categories include:

1. Diazepam nasal compositions.
2. Solubilized diazepam formulations.
3. Nasal delivery of diazepam for seizure clusters.
4. Dose regimens based on age, weight, and prior response.
5. Single-use spray devices.
6. Packaging and storage systems.
7. Pharmacokinetic or pharmacodynamic performance.
8. Methods for treating acute repetitive seizures.

The strongest claims are generally those that connect composition and use. A patent that covers only vitamin E as an excipient may be easier to design around than a claim covering diazepam at a defined concentration in a specified solvent system, delivered intranasally at a defined volume for a defined rescue indication.

Which patent claims create the main generic barriers?

The highest-value claim categories are likely to be:

Claim category	Generic barrier
Composition claims	High if the competitor must use a similar solvent system
Concentration and dose-volume claims	Moderate to high because nasal volume affects performance
Device claims	Moderate if the device is integrated with the formulation
Method-of-use claims	Moderate, depending on the scope and Orange Book listing
Pharmacokinetic claims	High if bioequivalence requires matching rapid absorption
Manufacturing claims	Variable; often avoidable through alternative processes
Packaging claims	Usually lower unless stability depends on the specific system

Patent strength depends on claim breadth, prosecution history, written-description support, expiration dates, and whether a generic can obtain approval without relying on patented labeling.

When does VALTOCO lose exclusivity?

VALTOCO received FDA approval in January 2020 as a new dosage form of an established active ingredient. Because diazepam was already approved, the product did not receive new chemical entity exclusivity. A 505(b)(2) product may receive three years of marketing exclusivity for a new clinical investigation essential to approval, subject to the statutory requirements.[2]

The three-year period would have expired in January 2023, absent a separate pediatric extension or another applicable exclusivity provision. That does not eliminate patent protection. Generic or hybrid applicants must still address relevant Orange Book patents and other enforceable rights.

Exclusivity or protection	Relevance to VALTOCO
New chemical entity exclusivity	Not applicable because diazepam is an established active ingredient
Three-year clinical-investigation exclusivity	Potentially applicable from the 2020 approval
Pediatric exclusivity	Applies only if FDA granted a qualifying six-month extension
Orphan-drug exclusivity	Not the principal protection identified for VALTOCO
Patent protection	Potentially extends beyond regulatory exclusivity
Trade secrets	May protect formulation processing, device assembly, and manufacturing controls

Exact patent expiration dates should be assessed from the current FDA Orange Book, USPTO records, patent-term-adjustment data, terminal disclaimers, and any continuation applications.[3]

What is the FDA and Orange Book status of VALTOCO?

VALTOCO is an FDA-approved prescription product under NDA 211635. It is listed as a diazepam nasal spray and is the reference product for any future ANDA or 505(b)(2) strategy directed to the same dosage form and route.[1][3]

FDA regulatory issues for a competing product include:

• Whether an ANDA can establish equivalence to the listed drug.
• Whether the product requires a 505(b)(2) application because of formulation or device differences.
• Whether a new clinical study is essential to approval.
• Whether the nasal device is sufficiently comparable.
• Whether the applicant can demonstrate equivalent dose delivery and pharmacokinetics.
• Whether the proposed labeling can omit patented seizure-cluster methods of use.

A conventional ANDA may be difficult if the formulation, device, or pharmacokinetic profile cannot be matched closely. A 505(b)(2) application may provide more flexibility, but it can require additional bridging studies and exposes the applicant to listed-patent certifications.

Which companies are challenging VALTOCO?

Publicly visible competitive pressure comes from products rather than a clearly established field of approved generic challengers. The principal commercial competitors include:

Product	Company	Route	Commercial position
VALTOCO	Neurelis	Intranasal	Ready-to-use diazepam rescue
Nayzilam	UCB	Intranasal	Midazolam rescue spray
Diastat and authorized generic versions	Multiple participants	Rectal	Established diazepam rescue option
Injectable benzodiazepines	Multiple participants	Intramuscular or intravenous	Clinical and emergency-use alternatives

Nayzilam is the closest branded route competitor, but it contains midazolam rather than diazepam. Its formulation, device, patent estate, and regulatory pathway are separate from VALTOCO’s.[4]

There is no biosimilar pathway for VALTOCO. Diazepam is a small molecule, so competitive entry would involve an ANDA, 505(b)(2) application, or an independently supported NDA rather than a biosimilar application.

How does VALTOCO compare with Nayzilam?

VALTOCO and Nayzilam compete for the same rescue-use occasion but rely on different benzodiazepines.

Factor	VALTOCO	Nayzilam
Active ingredient	Diazepam	Midazolam
Route	Intranasal	Intranasal
Indication	Seizure clusters	Seizure clusters
Dose presentation	5, 10, 15, 20 mg	5 mg per spray
High-dose administration	Two devices for 15 mg and 20 mg	Repeated dosing under label conditions
Formulation strategy	Vitamin E and alcohol-based solution	Separate formulation and device platform
Main substitution risk	Midazolam nasal spray	Diazepam nasal spray and rectal diazepam

VALTOCO’s broader dose range may simplify weight-based prescribing. Nayzilam’s lower per-spray dose may support a different dosing workflow. Formulary decisions can turn on caregiver preference, age range, prior benzodiazepine exposure, rescue-plan instructions, and payer contracting.

What commercial opportunities exist in VALTOCO excipients?

The most practical opportunities are in formulation design, supply, and lifecycle management.

Excipient substitution and design-around products

A competitor could investigate:

• Alternative lipophilic solubilizers.
• Cyclodextrin-based diazepam systems.
• Nonalcoholic cosolvent systems.
• Microemulsions or nanoemulsions.
• Mucoadhesive systems.
• Buffered aqueous systems.
• Dry-powder nasal delivery.
• Powdered or polymeric particles for sustained mucosal residence.

Each approach faces a tradeoff. A more complex system may improve solubility but increase device, scale-up, stability, or regulatory risk. A dry powder may remove alcohol and liquid-leakage concerns but require new device engineering and may be less suitable for patients with irregular breathing or acute convulsive activity.

Excipient supply and contract manufacturing

Suppliers can pursue value through:

• Pharmaceutical-grade vitamin E with controlled peroxide levels.
• Dehydrated alcohol with tight water-content specifications.
• Low-extractables container closure systems.
• Unit-dose pump components.
• Automated filling and crimping lines.
• Stability-indicating analytical methods.
• Nasal spray performance testing.

Excipient suppliers with established nasal, ophthalmic, or inhalation quality systems have an advantage because the main barrier is not simply compendial grade. It is reproducible performance in a low-volume, high-consequence delivery system.

Reformulation and global expansion

International markets may support reformulation opportunities where VALTOCO is not directly marketed or where local regulators require different excipient limits, device registrations, or packaging configurations. Potential adaptations include:

• Preservative-free unit-dose formats.
• Lower-alcohol products.
• Multi-dose systems with validated microbial controls.
• Temperature-resilient packaging.
• Pediatric-friendly dose formats.
• Alternative strengths for markets with different dosing conventions.

Global commercialization must account for excipient monographs, permitted daily exposure assessments, local nasal tolerability expectations, transport conditions, and device registration requirements.

What generic launch risks exist for VALTOCO?

A generic launch would face five principal risks.

First, the applicant must establish equivalent delivered dose and spray performance. A product that contains the same diazepam strength but delivers a different plume geometry or droplet-size distribution may not be acceptable.

Second, the formulation must achieve comparable systemic exposure. Diazepam absorption from the nose can be affected by solubility, viscosity, mucosal residence, device force, and nasal obstruction.

Third, the applicant must address listed patents through paragraph I, II, III, or IV certifications, as applicable. A paragraph IV certification could create litigation and a 30-month stay if the statutory conditions are met.[5]

Fourth, method-of-use patents may complicate labeling. A generic may seek a skinny label that omits patented uses, but the feasibility depends on the scope of the approved indication and the patent claims.

Fifth, commercial uptake requires caregiver confidence. Rescue products are often prescribed as part of an individualized seizure action plan. Physicians and caregivers may resist switching from a familiar device even after regulatory approval.

How strong is the VALTOCO patent estate?

The estate should be viewed as moderately defensible if it combines formulation, device, dosing, and method-of-use claims. Composition claims covering a narrow solvent system are more vulnerable to excipient substitution. Method claims may remain commercially important where the product’s principal value is its use in seizure clusters rather than diazepam itself.

The strongest practical protection is likely the combination of:

• Low-volume diazepam nasal solution.
• Specific solubilization and stability profile.
• Integrated single-use device.
• Weight- and age-based dosing.
• Clinical evidence supporting rapid rescue use.
• Manufacturing controls that preserve dose uniformity.

Patent risk should be assessed claim by claim. A generic that avoids one composition patent may still face device or method claims. Continuation patents and terminal disclaimers can also change the effective life of the estate.

Key Takeaways

• VALTOCO is a diazepam nasal spray approved by FDA in January 2020.
• Its formulation uses vitamin E and dehydrated alcohol to support a concentrated, low-volume nasal solution.
• The commercial differentiation depends on formulation, device, dose delivery, and caregiver usability.
• Diazepam’s established status means VALTOCO did not receive new chemical entity exclusivity.
• Regulatory exclusivity was shorter than the potential patent term, making Orange Book patents central to generic timing.
• The closest branded competitor is Nayzilam, a midazolam nasal spray marketed by UCB.
• The strongest generic barriers are likely pharmacokinetic matching, device equivalence, formulation patents, and method-of-use claims.
• Commercial opportunities include excipient substitution, nasal-device supply, contract manufacturing, dry-powder reformulation, and geographic expansion.
• There is no biosimilar pathway because diazepam is a small-molecule active ingredient.
• A successful competitor must solve both the IP problem and the caregiver-adoption problem.

FAQs

Can a generic VALTOCO use a different excipient from vitamin E?

Yes. A different excipient system may be possible, but the applicant must demonstrate acceptable solubility, stability, nasal tolerability, delivered dose, pharmacokinetics, and device performance. The alternative formulation must also avoid or successfully challenge relevant patent claims.

Is VALTOCO protected by orphan-drug exclusivity?

Orphan-drug exclusivity is not the principal protection associated with VALTOCO. The relevant commercial barriers are its 505(b)(2) regulatory history, listed patents, formulation technology, device configuration, and clinical-use evidence.

Could a dry-powder diazepam nasal product compete with VALTOCO?

Yes, but it would likely require substantial device and clinical development. A dry-powder product could reduce alcohol and liquid-stability issues while creating new risks involving powder dispersion, dose uniformity, nasal deposition, and patient handling.

Do excipient suppliers need to hold a drug application to sell ingredients for VALTOCO-type products?

Usually no. Suppliers must meet applicable pharmaceutical quality, manufacturing, documentation, and change-control requirements. The finished-drug sponsor remains responsible for excipient qualification and regulatory submissions.

What would be the fastest route to a competing diazepam nasal product?

The fastest route would depend on patent scope, reference-product listing, formulation similarity, and FDA’s determination of the appropriate pathway. An ANDA may be efficient if equivalence can be established. A 505(b)(2) application may be more practical when the formulation or device differs materially from VALTOCO.

References

1. U.S. Food and Drug Administration. (2024). VALTOCO (diazepam nasal spray) prescribing information. Neurelis, Inc.
2. U.S. Food and Drug Administration. (2024). Applications covered by Section 505(b)(2). FDA.
3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
4. U.S. Food and Drug Administration. (2024). NAYZILAM (midazolam) nasal spray prescribing information. UCB, Inc.
5. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. FDA.